PharmaCyte Biotech, Inc.
PMCB
Rank in Stocks
#30797
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development... PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
Share Price
$0.407
Last synced: 2026-11-09
Market Cap
$4.37M
Change (1 day)
13.06%
Change (1 year)
-53.64%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PharmaCyte Biotech, Inc. (PMCB)
Category
Healthcare
Operating Margin for PharmaCyte Biotech, Inc. (PMCB)
Operating Margin as of November 2026 TTM: 0.00%
According to PharmaCyte Biotech, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for PharmaCyte Biotech, Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -13,848.68% | 372.93% |
| 2012 | -2,928.27% | 850.92% |
| 2011 | -307.94% | -61.61% |
| 2010 | -802.11% | -15.19% |
| 2009 | -945.75% | 200.20% |
| 2008 | -315.04% | 2.19% |
| 2007 | -308.29% | -77.43% |
| 2006 | -1,365.83% | -31.51% |
| 2005 | -1,994.19% | -97.26% |
| 2004 | -72,681.49% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about PharmaCyte Biotech, Inc.'s operating margin
What was PharmaCyte Biotech, Inc.'s operating margin in 2025?
In 2025, PharmaCyte Biotech, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has PharmaCyte Biotech, Inc.'s operating margin changed since 2020?
From 2020 to 2025, PharmaCyte Biotech, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does PharmaCyte Biotech, Inc.'s operating margin compare with similar companies?
PharmaCyte Biotech, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.